CN112457387A - 一种厚壳贻贝寡肽及其用途 - Google Patents
一种厚壳贻贝寡肽及其用途 Download PDFInfo
- Publication number
- CN112457387A CN112457387A CN202011394154.5A CN202011394154A CN112457387A CN 112457387 A CN112457387 A CN 112457387A CN 202011394154 A CN202011394154 A CN 202011394154A CN 112457387 A CN112457387 A CN 112457387A
- Authority
- CN
- China
- Prior art keywords
- oligopeptide
- mytilus coruscus
- ala
- leu
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 53
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 53
- 241000143233 Mytilus coruscus Species 0.000 title claims abstract description 43
- 230000036772 blood pressure Effects 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 claims description 12
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 6
- 150000001413 amino acids Chemical group 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 241001537211 Perna canaliculus Species 0.000 claims description 2
- 230000004531 blood pressure lowering effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 35
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 7
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 7
- 230000002040 relaxant effect Effects 0.000 abstract description 4
- 230000008602 contraction Effects 0.000 abstract description 3
- 231100001083 no cytotoxicity Toxicity 0.000 abstract description 3
- 230000000975 bioactive effect Effects 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 46
- 102400000686 Endothelin-1 Human genes 0.000 description 20
- 101800004490 Endothelin-1 Proteins 0.000 description 20
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 19
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 19
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 239000007853 buffer solution Substances 0.000 description 10
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
- 229960000830 captopril Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 229920005654 Sephadex Polymers 0.000 description 6
- 239000012507 Sephadex™ Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229960002748 norepinephrine Drugs 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 238000005238 degreasing Methods 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- ZDLZKMDMBBMJLI-FDMDGMSGSA-N 2-[[2-[[(2s)-2-[[(e)-3-(furan-2-yl)prop-2-enoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetic acid Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)\C=C\C=1OC=CC=1)C1=CC=CC=C1 ZDLZKMDMBBMJLI-FDMDGMSGSA-N 0.000 description 2
- 108010048632 2-furanacryloyl-phenylalanyl-glycyl-glycine Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108090000913 Nitrate Reductases Proteins 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 101710178392 Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供一种厚壳贻贝寡肽及其用途,属于生物活性肽技术领域,厚壳贻贝寡肽的氨基酸序列为Leu‑Ala‑Ala‑Ser‑His或Tyr‑Glu‑Leu‑His‑Asp。本发明厚壳贻贝寡肽具有较高的ACE抑制活性,无细胞毒性,能增加血管内皮细胞(HUVEC细胞)中内源性舒张因子NO含量且降低内源性收缩因子ET‑1含量,亦即通过影响血管内皮细胞的功能来发挥其降压作用。本发明厚壳贻贝寡肽可用于制备具有调节血压作用的保健食品和/或药物。
Description
技术领域
本发明属于生物活性肽技术领域,具体涉及一种厚壳贻贝寡肽及其用途。
背景技术
高血压病大大增加了心脏、大脑、肾脏等器官患病的风险,也大大增加了患其他疾病的风险。因为高血压患者可以多年保持无症状状态,所以世界卫生组织称高血压是一种人类健康的“隐形杀手”。据统计,全世界有11.3亿人患有高血压,其中只有不到五分之一的高血压患者的病情可以得到控制,其中在2016年因心血管疾病(CVD)死亡的人数就占全球死亡人数的31%,是全球死亡的主要原因之一。其中高血压也是导致患者患有CVD病症的主要因素之一,因此,治疗和预防高血压已成为一项艰巨而必要的任务。
血管紧张素转换酶通过将血管紧张素I转化为具有强血管收缩作用的八肽血管紧张素II,并通过血管舒张作用降解缓激肽,这一过程在调节血压方面发挥重要作用。目前,市场上用于降压的药主要有阿米洛利、呋塞米、可乐定、氯沙坦等,这些药在发挥其本身的疗效之时也会给人体带来很大的副作用,例如咳嗽、味觉障碍、氮质血症、血管性水肿和皮疹等,严重者甚至导致死亡。因此,与合成血管紧张素转换酶抑制剂相比,天然的食源性血管紧张素转换酶抑制肽更安全、副作用更少、更容易被人体吸收,因而受到广泛关注,目前认为天然来源的ACE抑制剂可作为控制血压的替代治疗剂。
发明内容
本发明的目的在于一种ACE抑制活性高的厚壳贻贝寡肽。
本发明为实现上述目的所采取的技术方案为:
一种厚壳贻贝寡肽,其氨基酸序列为Leu-Ala-Ala-Ser-His或Tyr-Glu-Leu-His-Asp。
本发明厚壳贻贝寡肽具有较高的ACE抑制活性,无细胞毒性,能增加血管内皮细胞(HUVEC细胞)中内源性舒张因子NO含量且降低内源性收缩因子ET-1含量,亦即通过影响血管内皮细胞的功能来发挥其降压作用。因此,本发明ACE抑制肽可以作为潜在的天然降压药品或功能性食品进行研究,同时也为厚壳贻贝的商业价值的提高提供理论支持。
优选地,以寡肽序列为核心,任何对其进行的相应的调整或修饰。
优选地,寡肽具有降血压作用。
优选地,1mg/mL寡肽的ACE抑制率>85%。
本发明还公开了厚壳贻贝寡肽在制备具有调节血压作用的保健品和/或食品和/或药物中的用途。
优选地,厚壳贻贝寡肽在制备具有降血压作用的保健品和/或食品和/或药物中的用途。
优选地,ACE抑制肽在HUVEC细胞降压和调节中的用途。
本发明还公开了一种预防和/或治疗高血压的产品,含有Leu-Ala-Ala-Ser-His和/或Tyr-Glu-Leu-His-Asp作为活性成份。
本发明具有如下有益效果:本发明厚壳贻贝寡肽具有较高的ACE抑制活性,无细胞毒性,能增加血管内皮细胞(HUVEC细胞)中内源性舒张因子NO含量且降低内源性收缩因子ET-1含量,亦即通过影响血管内皮细胞的功能来发挥其降压作用。因此,本发明ACE抑制肽可以作为潜在的天然降压药品或功能性食品进行研究,同时也为厚壳贻贝的商业价值的提高提供理论支持。
附图说明
图1为本发明厚壳贻贝寡肽的ACE抑制活性;
图2为本发明厚壳贻贝寡肽对HUVEC细胞中NO水平的影响;
图3为本发明厚壳贻贝寡肽对HUVEC细胞中ET-1水平的影响。
具体实施方式
本发明允许各种修改及变形,其特定实施例进行了举例,下面进行详细说明。但并非要把本发明限定于公开的特别形态之意,相反,本发明包括与由权利要求项所定义的本发明思想一致的所有修改、均等及替代。
这些实施例只用于更具体地说明本发明,根据本发明的要旨,本发明的范围并非限定于这些实施例,这是所属技术领域的技术人员不言而喻的。
本公开实施例提供一种厚壳贻贝寡肽的制备流程为:
厚壳贻贝肉室温解冻清洗→剪碎→加入乙酸乙酯脱脂→风干→粉碎→特定蛋白酶酶解→高温灭活,冷却至室温→高速离心除沉淀→分离、纯化、测序。
本公开实施例还提供一种厚壳贻贝寡肽的制备方法,包括:
1)将冷冻的厚壳贻贝肉室温流水解冻,清洗干净,低温烘干表面水分,解剖绞碎,加乙酸乙酯浸泡24-72h,脱脂过程中不断搅拌,脱脂后的样品经真空抽滤去除乙酸乙酯(旋蒸回收)后,烘干,粉碎得厚壳贻贝粉;
2)按料液比1:20-60将厚壳贻贝粉中加水,再加入1-5%胰蛋白酶,在pH 7-9、30-50℃条件下酶解3.0-5.0h,反应结束后,灭酶,得酶解液;
3)选用截留分子量为1kDa的超滤膜对步骤2)所得厚壳贻贝酶解液进行超滤,得到<1kDa酶解物,冷冻干燥得;
4)将步骤3)所得<1kDa酶解物配置成40-60mg/mL的溶液,离心,取上清液过0.45μm微滤膜,以充分除去不溶性杂质;取3mL样品并通过恒流泵恒流上样至QFF离子交换层析柱中,依次按照Tris-HCl缓冲液、Tris-HCl(含0.05M NaCl)缓冲液、Tris-HCl(含0.1M NaCl)缓冲液、Tris-HCl(含0.25M NaCl)缓冲液、Tris-HCl(含0.5M NaCl)缓冲液逐级洗脱,并在214nm紫外波长下收集出峰组分,按峰合并收集液,比较各峰的抗氧化活性,选择活性较高组分冻干,备用;
5)将步骤4)所得组分溶液3mL加入到Sephadex G-25凝胶过滤层析色谱柱中,以超纯水为流动相,流速为0.4-0.6mL/min,每10min收集一管,并于214nm吸收波长处检测,按峰合并收集液,比较各峰的抗氧化活性,选择活性较高组分冻干,备用;
6)将步骤5)所得组分溶于超纯水并过0.22μm微孔滤膜后,吸取3μL加载到Zorbax300SB-C18柱(4.6×250mm)上进行分离,洗脱液包含两种,一种A液0.06%TFA的水,一种B液含有0.05%TFA的乙腈,使用梯度洗脱:0-4min,1%B;4-16min,1%-9%B;16-24min,9%-50%B;24-24.5min,50%-100%B;24.5-30.5min,100%B,在280nm处测吸光度值,并分别收集各组份冻干,经测定存在氨基酸序列为Leu-Ala-Ala-Ser-His的组分,分子量为497.55Da;存在氨基酸序列为Tyr-Glu-Leu-His-Asp的组分,其分子量为675.70Da。
以下结合实施例对本发明作进一步详细描述:
实施例1:
一种厚壳贻贝寡肽的制备方法,包括:
1)将冷冻的厚壳贻贝肉室温流水解冻,清洗干净,低温烘干表面水分,解剖绞碎,加乙酸乙酯浸泡48h,脱脂过程中不断搅拌,脱脂后的样品经真空抽滤去除乙酸乙酯(旋蒸回收)后,烘干,粉碎得厚壳贻贝粉;
2)按料液比1:40将厚壳贻贝粉中加水,再加入3%胰蛋白酶,在pH 8、40℃条件下酶解4.0h,反应结束后,置于100℃的沸水中加热灭酶10min,得酶解液;
3)选用截留分子量为1kDa的超滤膜对步骤2)所得厚壳贻贝酶解液进行超滤,得到<1kDa酶解物,冷冻干燥得;
4)将QFF通过玻璃棒引流缓缓倒入层析柱中(柱体积约200mL)。等上层沉降完成后,用双蒸水清洗层析柱,清洗3~5个柱体积,充分洗去残留的乙醇。再用Tris-HCl缓冲溶液(0.05M,pH 8.0)平衡至pH恒定。将步骤3)所得<1kDa酶解物配置成50mg/mL的溶液,离心,取上清液过0.45μm微滤膜,以充分除去不溶性杂质;取3mL样品并通过恒流泵恒流上样至QFF离子交换层析柱中,依次按照Tris-HCl缓冲液、Tris-HCl(含0.05M NaCl)缓冲液、Tris-HCl(含0.1M NaCl)缓冲液、Tris-HCl(含0.25M NaCl)缓冲液、Tris-HCl(含0.5M NaCl)缓冲液逐级洗脱,并在214nm紫外波长下收集出峰组分,按峰合并收集液,比较各峰的抗氧化活性,选择活性较高组分冻干,备用;
5)葡聚糖凝胶Sephadex G-25经适量超纯水浸泡过夜,使凝胶充分溶胀,并弃去上层漂浮的颗粒,用抽滤装置对其进行脱气泡处理。将层析柱(直径×柱长:2cm×120cm)垂直固定于铁架台上,检漏后加入适量双蒸水,将Sephadex G-25沿玻璃棒连续缓慢的加入到色谱柱中,让其自然沉降,之后以2倍柱体积量的超纯水平衡色谱柱。开启恒流泵过夜,用流水压实胶柱体。色谱柱平衡后,将步骤4)所得组分溶液3mL加入到Sephadex G-25凝胶过滤层析色谱柱中,以超纯水为流动相,流速为0.5mL/min,每10min收集一管,并于214nm吸收波长处检测,按峰合并收集液,比较各峰的抗氧化活性,选择活性较高组分冻干,备用;
6)将步骤5)所得组分溶于超纯水并过0.22μm微孔滤膜后,吸取3μL加载到Zorbax300SB-C18柱(4.6×250mm)上进行分离,洗脱液包含两种,一种A液0.06%TFA的水,一种B液含有0.05%TFA的乙腈,使用梯度洗脱:0-4min,1%B;4-16min,1%-9%B;16-24min,9%-50%B;24-24.5min,50%-100%B;24.5-30.5min,100%B,在280nm处测吸光度值,并分别收集各组份冻干得H1-H8组份;
7)将H1-H8共8条多肽的氨基酸序列和分子量,用Applied Biosystems 494Protein Sequencer(Perkin Elmer,USA)测定8条肽N-末端氨基酸序列,根据AppliedBiosystems提供的标准程序进行Edman降解。
通过Q-TOF质谱仪(Micromass,Waters,USA)与电喷雾电离(ESI)源结合准确测定8种肽的分子量。电离是在毛细管电压为3500V的正模式下进行的。氮气在雾化过程中保持在40psi,在蒸发过程中保持9L/min在350℃时。以质心模式从M/Z100到2000收集数据,如表1。
表1厚壳贻贝多肽H1-H8的出峰时间、氨基酸序列和分子量
实施例2:
厚壳贻贝寡肽的ACE抑制活性测试
主要试剂:盐酸(分析纯)、氯化钠(分析纯)、氢氧化钠(分析纯),购自国药集团化学试剂有限公司;N-2-羟乙基哌嗪-N'-2-乙磺酸(HEPES),购自Solarbio公司;血管紧张素转换酶(ACE)、FAPGG(N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly),购自美国Sigma公司。
试剂的配制:80mM HEPES缓冲液(pH 8.3,Cl-浓度为300mM):HEPES 1.910g,NaCl1.755g,双蒸水溶解后,NaOH调节pH至8.3再补充水至100mL,置4℃备用;FAPGG溶液(1mM):取3.994mg FAPGG粉末加HEPES缓冲液,混合溶解,定容至10mL,置4℃避光保存;ACE抑制剂(待测肽):称取适量的活性肽粉末,用HEPES缓冲液为溶剂配制成一系列浓度的活性肽溶液;ACE溶液(0.1U/mL):将0.25U ACE溶于2.5mL的HEPES缓冲液中,即可得到0.1U/mLACE溶液,置-20℃保存备用。
ACE抑制活性的测定:在96孔板上按表2设计添加反应物,在340nm处分别测定空白孔和样品孔的初始吸光度(A1,B1),在37℃的恒温培养条件下反应30min,再测定其吸光度(A2,B2)。ACE抑制活性计算公式如下:
其中:Bi(B1-B2)为样品孔吸光值在30min的变化:Ai(A1-A2)为空白孔吸光值在30min的变化。
表2 ACE抑制活性测定
数据处理:实验结果用平均值±标准偏差表示(n=3),并使用Origin和SPSS 22.0软件进行作图和数据分析。
厚壳贻贝寡肽的ACE抑制活性如图1,图中CP为卡托普利,CSY为到Sephadex G-25凝胶过滤层析得活性较高组分,CSY-1为Leu-Ala-Ala-Ser-His,CSY-2为Tyr-Glu-Leu-His-Asp,CSY-3为Gln-Glu-Thr-Tyr。可以看出,本发明厚壳贻贝寡肽Tyr-Glu-Leu-His-Asp具有较好的ACE抑制活性,同时寡肽Leu-Ala-Ala-Ser-His和Gln-Glu-Thr-Tyr也具有ACE抑制活性。
实施例3:
厚壳贻贝寡肽对HUVEC细胞中NO水平和ET-1水平的影响
材料:人脐静脉内皮细胞(Human Umbilical Vein Endothelialm Cell,HUVEC)购于中国科学院上海细胞库。
主要试剂:DMEM培养基、特级胎牛血清(FBS)、青霉素-链霉素液、胰酶-EDTA、PBS、四甲基偶氮(MTT)、卡托普利(Cap)、去甲肾上腺素(NE),购自北京索莱宝科技有限公司;二甲亚砜(DMSO)、无水乙醇,购自国药集团化学试剂有限公司;NO试剂盒、内皮素-1(ET-1)试剂盒,购自南京建成生物工程。
UVEC细胞的培养:HUVEC细胞使用DMEM+10%胎牛血清(FBS)+1%双抗(青霉素-链霉素)培养液进行培养。培养流程如下:复苏后的细胞置于含5%CO2培养箱中,37℃培养,12h后换液,等到细胞生长至能覆盖瓶底80%-90%时,用胰酶进行消化并传代。取对数生长期的HUVEC细胞作为实验材料。
HUVEC细胞毒性试验(MTT法):将对数生长期的HUVEC,接种于若干96孔培养板。每孔180μL,细胞数0.9×104个/孔,置于37℃、5%CO2的恒温箱中孵育24h。样品组加入20μL寡肽其终浓度分别为100、200、300、400和500μM,空白组加入20μL PBS,孵育24h后,再加入20μL MTT孵育4h后弃去培养液,再加入150μL DMSO在37℃下孵育10min后,用酶标仪在570nm测量吸光度值,计算细胞存活率。
细胞存活率计算公式:细胞存活率(%)=(实验组/对照组)×100
实验分组及处理:将对数生长期的HUVEC,接种于若干6孔培养板。每孔1.8mL,细胞数3.5×105个/孔,置于37℃、5%CO2的恒温箱中孵育24h。随机分组如下:
(1)空白对照(Control)组:不加任何试剂处理细胞;
(2)卡托普利(Cp)组:加入卡托普利终浓度为1μM;
(3)去甲肾上腺素(NE)组:加入去甲肾上腺素终浓度为0.5μM;
(4)CSY-1组:分别加入寡肽Leu-Ala-Ala-Ser-His终浓度为50μM、100μM、200μM;
(5)CSY-2组:分别加入寡肽Tyr-Glu-Leu-His-Asp终浓度为50μM、100μM、200μM。
HUVEC细胞内NO含量测定:采用硝酸还原酶试剂盒。其测定原理:NO化学性质活泼,在体内代谢转化为硝酸盐(NO3 -)和亚硝酸盐(NO2 -),而亚硝酸盐(NO2 -)又进一步转化为硝酸盐(NO3 -),本法利用硝酸还原酶特异性将硝酸盐(NO3 -)还原为硝酸盐(NO2 -),通过在550nm测定其吸光值,计算NO含量。作用24h后,弃去培养液,用PBS洗三次,再使用细胞刮分别将每组细胞刮下收集到EP管中,在冰水浴中用细胞破碎仪将细胞破碎,加入300μL PBS,然后按NO试剂盒上的步骤进行操作。
HUVEC细胞内ET-1含量测定:采用双抗体一步夹心法酶联免疫吸附试验(ELISA)。其原理:往预先包被内皮素1(ET-1)抗体的包被微孔中,依次加入标本、标准品、HRP标记的检测抗体,经过温育并彻底洗涤。用底物TMB显色,TMB在过氧化氢酶的催化下转化成蓝色,并在酸的作用下最终转化成黄色。颜色的深浅与样品中的内皮素1(ET-1)呈正相关。用酶标仪在450nm波长处测其吸光值,计算样品浓度。ET-1含量测定的具体步骤按试剂盒说明书进行操作。
与空白组相比,在100-400μM浓度范围内,CSY-1组和CSY-2组的细胞存活率均在90%以上。
厚壳贻贝寡肽对HUVEC细胞中NO水平的影响如图2所示,与空白对照组相比,卡托普利(Cp)组NO含量显著上升。此外,CSY-1组和CSY-2组中寡肽Leu-Ala-Ala-Ser-His和Tyr-Glu-Leu-His-Asp分别以50、100、200μM的浓度作用于细胞,结果显示NO含量呈现剂量依赖性,说明寡肽Leu-Ala-Ala-Ser-His和Tyr-Glu-Leu-His-Asp能抑制细胞中NO的生成。
厚壳贻贝寡肽对HUVEC细胞中ET-1水平的影响如图3所示,与空白对照组相比,卡托普利(Cp)组ET-1含量显著下降。此外,CSY-1组和CSY-2组中寡肽Leu-Ala-Ala-Ser-His和Tyr-Glu-Leu-His-Asp分别以50、100、200μM的浓度作用于细胞,ET-1含量呈现剂量依赖性。同时,去甲肾上腺素(NE)抑制细胞中ET-1的释放,且加入ACE抑制肽后,ET-1含量显著下降,说明寡肽Leu-Ala-Ala-Ser-His和Tyr-Glu-Leu-His-Asp能抑制细胞中ET-1的生成。
通过寡肽Leu-Ala-Ala-Ser-His和Tyr-Glu-Leu-His-Asp对NO和ET-1两种因子的复合作用结果表明,寡肽Leu-Ala-Ala-Ser-His和Tyr-Glu-Leu-His-Asp无明显毒性,并能促进HUVEC细胞中内源性舒张因子一氧化氮(NO)的释放和抑制内源性收缩因子内皮素(ET-1)的生成,表明这寡肽Leu-Ala-Ala-Ser-His和Tyr-Glu-Leu-His-Asp对HUVEC细胞具有一定的降压和调节功能。因此,在体内环境下,寡肽Leu-Ala-Ala-Ser-His和Tyr-Glu-Leu-His-Asp可以通过影响血管内皮细胞的功能来发挥其降压作用。
上述实施例中的常规技术为本领域技术人员所知晓的现有技术,故在此不再详细赘述。
以上实施方式仅用于说明本发明,而并非对本发明的限制,本领域的普通技术人员,在不脱离本发明的精神和范围的情况下,还可以做出各种变化和变型。因此,所有等同的技术方案也属于本发明的范畴,本发明的专利保护范围应由权利要求限定。
Claims (7)
1.一种厚壳贻贝寡肽,其氨基酸序列为Leu-Ala-Ala-Ser-His或Tyr-Glu-Leu-His-Asp。
2.根据权利要求1所述的一种厚壳贻贝寡肽,其特征在于:以所述寡肽序列为核心,任何对其进行的相应的调整或修饰。
3.根据权利要求1所述的一种厚壳贻贝寡肽,其特征在于:所述寡肽具有降血压作用。
4.根据权利要求1所述的一种厚壳贻贝寡肽,其特征在于:1mg/mL所述寡肽的ACE抑制率>85%。
5.权利要求1所述的厚壳贻贝寡肽在制备具有调节血压作用的保健品和/或食品和/或药物中的用途。
6.根据权利要求5所述的用途,其特征在于:所述厚壳贻贝寡肽在制备具有降血压作用的保健品和/或食品和/或药物中的用途。
7.一种预防和/或治疗高血压的产品,含有Leu-Ala-Ala-Ser-His和/或Tyr-Glu-Leu-His-Asp作为活性成份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011394154.5A CN112457387A (zh) | 2020-12-03 | 2020-12-03 | 一种厚壳贻贝寡肽及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011394154.5A CN112457387A (zh) | 2020-12-03 | 2020-12-03 | 一种厚壳贻贝寡肽及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112457387A true CN112457387A (zh) | 2021-03-09 |
Family
ID=74805320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011394154.5A Withdrawn CN112457387A (zh) | 2020-12-03 | 2020-12-03 | 一种厚壳贻贝寡肽及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112457387A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114031669A (zh) * | 2021-12-01 | 2022-02-11 | 浙江海洋大学 | 厚壳贻贝抗氧化活性肽及其制备和应用 |
CN114057837A (zh) * | 2021-12-07 | 2022-02-18 | 浙江海洋大学 | 一组从厚壳贻贝肉中分离的具有肝保护功能的抗氧化肽及其制备方法和应用 |
CN115245558A (zh) * | 2021-12-27 | 2022-10-28 | 浙江海洋大学 | 一种厚壳贻贝免疫活性六肽脂质体的制备方法 |
-
2020
- 2020-12-03 CN CN202011394154.5A patent/CN112457387A/zh not_active Withdrawn
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114031669A (zh) * | 2021-12-01 | 2022-02-11 | 浙江海洋大学 | 厚壳贻贝抗氧化活性肽及其制备和应用 |
CN114031669B (zh) * | 2021-12-01 | 2023-05-02 | 浙江海洋大学 | 厚壳贻贝抗氧化活性肽及其制备和应用 |
CN114057837A (zh) * | 2021-12-07 | 2022-02-18 | 浙江海洋大学 | 一组从厚壳贻贝肉中分离的具有肝保护功能的抗氧化肽及其制备方法和应用 |
CN114057837B (zh) * | 2021-12-07 | 2024-01-26 | 浙江海洋大学 | 一组从厚壳贻贝肉中分离的具有肝保护功能的抗氧化肽及其制备方法和应用 |
CN115245558A (zh) * | 2021-12-27 | 2022-10-28 | 浙江海洋大学 | 一种厚壳贻贝免疫活性六肽脂质体的制备方法 |
CN115245558B (zh) * | 2021-12-27 | 2024-05-28 | 浙江海洋大学 | 一种厚壳贻贝免疫活性六肽脂质体的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112457387A (zh) | 一种厚壳贻贝寡肽及其用途 | |
Wang et al. | Purification and identification of a ACE inhibitory peptide from oyster proteins hydrolysate and the antihypertensive effect of hydrolysate in spontaneously hypertensive rats | |
Suetsuna et al. | Identification of antihypertensive peptides from peptic digest of two microalgae, Chlorella vulgaris and Spirulina platensis | |
CN110724178B (zh) | 一种金枪鱼白肉ace抑制肽及其制备方法 | |
CN111647043B (zh) | 含有Hyp-Gly序列的一类抗血小板和抗血栓功能的寡肽 | |
CN108484723B (zh) | 浒苔来源的血管紧张素转化酶抑制肽及其制备方法和应用 | |
WO2020108629A1 (zh) | 一种多肽rdp1及其提纯方法与应用 | |
CN111518164B (zh) | Ace抑制肽p2、其应用及其制备方法 | |
CN110759965B (zh) | 一种金枪鱼红肉ace抑制肽及其制备方法 | |
CN114292311A (zh) | 胰脂肪酶抑制肽及其应用 | |
EP3945093A1 (en) | Synthetic peptide brap and use thereof in preparation of anti-inflammatory medicine for covid-19 | |
CN111995659B (zh) | 一种来源于牡丹籽粕的ace抑制肽 | |
CN109206483A (zh) | 一种贻贝来源的ace抑制及抗肿瘤活性肽 | |
CN112521446B (zh) | 一种ace抑制肽及其用途 | |
CN114195857B (zh) | 一种降压肽及其制备方法和应用 | |
CN112028970B (zh) | 一种牡丹籽粕ace抑制肽及其制备方法与应用 | |
CN108101960B (zh) | 一种具有ace抑制活性和抗肿瘤的多肽分子及其制备方法 | |
CN111116712B (zh) | 一种具有ace抑制活性的六肽及其应用 | |
CN111087446B (zh) | 一种抑制血管紧张素转换酶的十肽及其应用 | |
CN111499691B (zh) | Ace抑制肽p1、其应用及其制备方法 | |
CN112125952B (zh) | 一种猪源ace抑制活性多肽与药物组合物或食品及应用 | |
KR101646325B1 (ko) | 해양 미세조류 스피루리나 속 소화가수분해물 및 이로부터 유래된 펩타이드를 유효성분으로 함유하는 고혈압 예방 및 치료용 조성물 | |
CN113444145B (zh) | 一种聚球藻血管紧张素转化酶抑制肽及其制备方法与应用 | |
CN110981952A (zh) | 一种对乙醇诱导损伤肝细胞具有保护作用的乳铁蛋白修饰肽的制备方法及应用 | |
CN111004308B (zh) | 一种抑制血管紧张素转换酶的七肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210309 |
|
WW01 | Invention patent application withdrawn after publication |